PBZ-SR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pbz-sr, and what generic alternatives are available?
Pbz-sr is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in PBZ-SR is tripelennamine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the tripelennamine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PBZ-SR?
- What are the global sales for PBZ-SR?
- What is Average Wholesale Price for PBZ-SR?
Summary for PBZ-SR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Patent Applications: | 712 |
| DailyMed Link: | PBZ-SR at DailyMed |
US Patents and Regulatory Information for PBZ-SR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PBZ-SR | tripelennamine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 010533-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PBZ-SR | tripelennamine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 010533-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
